Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 304

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 304
---
 disputes with Iris. The enforceability of similar forum selection clauses in other companies’ bylaws or similar governing documents has been challenged in legal proceedings, and it is possible that in connection with any action a court could find the forum selection clause contained in Iris’s bylaws to be inapplicable or unenforceable in such action.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ​ |

160

TABLE OF CONTENTS

### INFORMATION ABOUT IRIS

#### Introduction
Iris is a blank check company incorporated on November 5, 2020, as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Although Iris is not limited to a particular business or industry for purposes of consummating a business combination, Iris has focused its search for an initial business combination on businesses where Iris believes it can capitalize on the ability of its team to identify, acquire, and operate a business or businesses that can benefit from their established global relationships and operating experience. Iris has not commenced any operations nor generated any revenue to date. Iris generates non-operating income in the form of interest income on investments held in its Trust Account and changes in the fair value of its warrant liabilities.

#### IPO
The registration statement for Iris’s IPO was declared effective on March 4, 2021. On March 9, 2021, Iris consummated the IPO of 27,600,000 Units, which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units, at $10.00 per Unit, generating gross proceeds of $276,000,000.

Simultaneously with the closing of the IPO, Iris consummated the sale of 5,013,333 private placement warrants to the Sponsor and Cantor, the representative of the underwriters of the IPO, at a price of $1.50 per private placement warrant, generating gross proceeds of $7,520,000. Each warrant (including the private placement warrants and the warrants included as part of the Units) entitles the holder to purchase one share of common stock at a price of $11.50 per share.

Following the closing of the IPO on March 9, 2021, $276,000,000 (approximately $10.00 per Unit) from the net proceeds of the sale of the Units in the IPO, including the proceeds from the sale of the private placement warrants, was